- Candel Therapeutics (CADL, Financial) added to multiple Russell Indexes in 2025.
- Maintained presence in the Russell 3000® Index from 2024.
- Key developments in biological immunotherapy for cancer treatment underway.
Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical firm focused on developing multimodal biological immunotherapies, has expanded its market presence by being included in several prestigious Russell Indexes during the 2025 Russell US Indexes reconstitution. This significant inclusion involves the Russell 2500 Value® Index, Russell Small Cap Value® Index, Russell 2000 Value® Index, Russell Microcap Value® Index, and Russell 3000E® Value Index. Importantly, Candel continues to be part of the broad-market Russell 3000® Index, which it joined in 2024.
This expansion of index presence highlights the advancements Candel has made in its clinical programs and discovery efforts aimed at leveraging the immune system to tackle cancer. The company is currently gearing up for a potential Biologics License Application for their lead product candidate, CAN-2409, targeted at intermediate-to-high-risk localized prostate cancer. Candel is actively advancing its innovative multimodal immunotherapy platform across various solid tumors.
The inclusion in these widely-followed Russell Indexes represents a crucial milestone for Candel (CADL, Financial), offering enhanced visibility and engagement with the investment community. The Russell Indexes, managed by FTSE Russell, benchmark approximately $10.6 trillion in assets, providing significant exposure and credibility to companies included.
As Candel continues to push the boundaries in cancer treatment through its multimodal approaches, the company anticipates leveraging its index presence to further its mission and achieve broader market outreach.
